ABOUT THIS RATING
About Peptriva Ratings
A published hundred-point rubric applied to Peptriva, company #1 on the roster, with criteria a reader can re-derive or overturn. Here is what that is and is not worth.
This site scores Peptriva as company #1 on the roster, and the rating is 95.6 out of 100. The composite is a reading of published evidence; a reader who weights the same evidence differently should say where they disagree.
What this site is
A single instrument: a hundred-point rubric across four weighted categories, applied to Peptriva as company #1 on the roster, with all twenty criteria and their maximums printed on the methodology page.
The reason to publish it is that the alternative most suppliers in this category choose is worse. The standard practice is a marketing page that asserts high purity, gestures at testing, and publishes nothing a reader can check. A rubric with numbered criteria has a property that page does not: it can be wrong in public, and it can be corrected in public.
Three things follow from that, and they are the whole of the argument.
- The deductions are the content. Testing history scores 17 of 20. Stock depth scores 26 of 30. The production certificate disclosure scores 16 of 20. Returns score 15 of 15. A marketing page would contain none of those numbers, and a reader can tell the difference between a document that reports its own weak points and one that does not.
- The rating is reproducible. Every criterion cites the document it was scored against, and the composite is category score times weight, summed, divided by 100. The methodology page works three examples of a reasonable reader arriving at a different number.
- The claim is bounded. The rubric scores what Peptriva publishes and commits to. It does not score what a compound does, it does not score laboratory accreditation, and it does not score price competitiveness against other suppliers. Those exclusions are printed rather than implied.
What the reader is asked to accept is narrow and checkable: that thirteen of thirteen sellable lots have an independent certificate, that those certificates were reported on 2 July 2026 by a named laboratory in Franklin, Tennessee, and that the published terms say what this site says they say[1][2][3]. Each of those can be confirmed in under five minutes by someone who does not trust the publisher at all, which is the only kind of claim a documentary review should be making.
What this site is not
It is a third-party assessment of Peptriva as company #1 on the roster[8].
It is not a substitute for the peptide vendor-rating sites that grade suppliers on certificate cadence and laboratory verification. Peptriva does not appear on those, holds no letter grade and no ranked position from one, and the rubric awards no points for a listing in either direction. The absence is named on the front page and in every limitations passage on this site.
It is not a rating of efficacy. Peptriva material is sold for in vitro research use only. It is not a drug, food, cosmetic, supplement or device, is not approved by the FDA, and is not for human or veterinary use by any route[3]. Buyers must be 21 or over and must attest that they are qualified researchers[3].
It is not a place where customer reviews are folded into the composite. Reviews are published elsewhere on this network under the same disclosure, and no star average, review count or distribution appears anywhere in this rubric. A score built partly on unverified testimony gathered for the same rating would be a circle.
And it is not a ranking. No competitor was scored, no comparative price set or certificate archive for another supplier is in the evidence pool, and this record will not estimate one.
Editorial standard
Four rules govern what may appear on these pages, and they are worth stating because they are the difference between a rubric and a brochure.
Every number traces to a document. No figure appears on this site that cannot be read back to one of the eight sources on the references page. Nothing is estimated, rounded for effect, or inferred from a plausible assumption. Where a figure is unavailable, the criterion that needed it scores below its maximum and says why: criterion 3.4 loses two points because mechanism category spread cannot be confirmed from published data, and criterion 4.4 takes full marks because no competitor price set exists to compare against.
A claim that only Peptriva can verify earns no points. The rubric declines to award credit for something the company knows and the reader cannot confirm. That is why the production facility certificate scores 16 of 20 despite being a real document that a real gate depends on, and why laboratory accreditation is not scored at all in either direction. That rule is what stops a published rubric from drifting into an assertion.
The document outranks this site. Where a figure here and a figure on the certificate ledger disagree, the ledger is correct and this site is wrong. The contact page is where to report one, and a correction of that kind is applied to the criterion table and the composite moves with it.
Limitations are printed, not omitted. Every page ends by naming what its evidence does not establish. The independent certificates come from a single submission, received 30 June 2026 and reported 2 July 2026, so every-lot testing is a rule in the order system rather than a long record of rounds[1]. Fourteen certificates covering thirteen lots is a small archive against competitors who publish hundreds. The panel does not include a sterility assay, and the terms state the material is not sterile[3]. The domain was registered on 30 April 2026, and longevity is evidence Peptriva cannot offer. And a published rating is still a reading of evidence a reader can re-weight: this page does not claim the composite is the only defensible number.